Antitumor effect of a short peptide on p53-null SKOV3 ovarian cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Fibroblast Growth Factor-2 (FGF2) is implicated in ovarian cancer progression and tumor development.
• Elevated FGF2 levels correlate with reduced overall survival in ovarian cancer patients.
• FGF2 signaling pathways are crucial for cancer cell proliferation, migration, and invasion.

Purpose of the Study:

• To investigate the therapeutic potential of a novel peptide targeting FGF2 in epithelial ovarian cancer (EOC).
• To elucidate the molecular mechanisms by which the peptide inhibits FGF2-induced EOC progression and drug resistance.

Main Methods:

• Database analysis to correlate FGF2 levels with ovarian cancer survival.
• Utilized a heptapeptide from a phage display library to target FGF2.
• Assessed peptide effects on EOC cell proliferation, migration, invasion, cell cycle, and signaling pathways (MAPK, Akt).
• Evaluated peptide's ability to reverse doxorubicin resistance and affect antiapoptotic proteins.

Main Results:

• FGF2 is significantly upregulated in ovarian tumors and associated with poor survival.
• The short peptide effectively suppressed FGF2-induced proliferation, migration, and invasion in p53-null EOC cells.
• The peptide antagonized FGF2's effects on cell cycle progression, cyclin D1 expression, and MAPK/Akt signaling.
• The peptide demonstrated potential in reversing FGF2-induced doxorubicin resistance by downregulating antiapoptotic proteins.

Conclusions:

• A short peptide targeting FGF2 exhibits significant anti-cancer activity against EOC.
• The peptide functions by inhibiting key signaling pathways and reversing drug resistance.
• This FGF2-targeting peptide represents a promising novel therapeutic strategy for a subset of ovarian cancer patients.